Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location
Trial ID or NCT#
Status
RECRUITING
Purpose
This is a randomized controlled trial to compare three currently available management strategies for women with a persisting pregnancy of unknown location (PPUL), which makes them at-risk for ectopic pregnancy. We will recruit hemodynamically stable women with a confirmed PPUL to be randomized to one of three strategies: 1) Uterine evacuation followed by methotrexate (MTX) for some (those that have evidence of a non visualized ectopic pregnancy) 2) Empiric treatment with MTX for all 3) Expectant management. Randomization will be 1:1:1 into these three arms. After randomization, they will be followed and treated clinically as is indicated by the progression of their condition. Primary outcome measures: uneventful decline of hCG to 5 IU/mL.
Official Title
Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location - a Randomized Clinical Trial of Women at Risk for an Ectopic Pregnancy: Active Treatment Versus No Treatment
Eligibility Criteria
- - Female with a persisting pregnancy of unknown location: - A pregnancy of unknown location is defined as a pregnancy in a woman with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging. A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa. Ultrasound must be performed within 7 days prior to randomization. - Persistence of hCG is defined as at least 2 serial hCG values (over 2-14 days), showing < 15% rise per day, or < 50% fall between the first and last value. - Patient is hemodynamically stable, hemoglobin >10 mg/dL - Greater than or 18 years of age
- - Hemodynamically unstable in need of acute treatment - Most recent hCG > 5000 mIU/mL - Patient obtaining care in relation to a recently completed pregnancy (delivery, spontaneous or elective abortion) - Diagnosis of gestational trophoblastic disease - Subject unwilling or unable to comply with study procedures - Known hypersensitivity to MTX - Presence of clinical contraindications for treatment with MTX - Prior medical or surgical management of this gestation - Subject unwilling to accept a blood transfusion
Contact us to find out if this trial is right for you.
Contact
Oshra Sedan, PhD
408-688-9892
View on ClinicalTrials.gov
